Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds 
instance, building a model without any information of the cell lines, the model will be not capable of predicting cell line A to be more resistant than cell line B to drug C, which is the main aim of integrating chemical and genomic features in our models.
We therefore extended our machine learning models to include as input chemical features from the drugs, besides the molecular characterization of the cell lines (see Fig 1) . This integrative approach not only integrates two complementary streams of information, but also allows the model to be trained with much larger amounts of data, which is often a key factor to improve predictive performance (see Fig 2) .
Consequently, data was pre-processed to include 689 chemical descriptors of the drugs and 138 genomic features for differentiating the cell lines, resulting in an input space of 827 features.
Chemical descriptors were generated with PaDEL software [19] from simplified molecular-input line entry system (SMILES) structures. Descriptors include physicochemical features such as weight, lipophilicity, rule of five, and additionally fingerprints of the drugs (for details see "Materials and Methods" section, "Features" subsection, and http://padel.nus.edu.sg/software/padeldescriptor/). For building our model, we used GDSC screening data from 608 genomically characterised cell lines and 111 drugs for which chemical information were available (see Fig 2 and Methods for details). The published version of this matrix holds 38,930 IC 50 values (~58% of the total, due to technical and logistic reasons).
We performed an 8-fold cross-validation, where the test set of each fold was not used for training so as to measure the predictive power of the resulting models across all drugs rather than for each drug separately. Neural networks were able to impute missing log(IC 50 ) values on the test sets with an averaged Pearson correlation coefficient (R p ), coefficient of determination (R 2 ) and root mean square error (RMSE) (Text S1) of 0.85, 0.72 and 0.83 across all 111 drugs, respectively ( Fig 3A) . Alternatively, random forests achieved comparable performances (R p of 0.85, R 2 of 0.72 and RMSE of 0.84; full details in supplementary materials). Furthermore, we conducted a blind test using 13,565 new experimental IC 50 values only received after training our models in order to verify our cross-validation results (drug-to-cell line matrix updated by ~18%, with these newly generated IC 50 s exclusively used as the blind test set).
The results on the blind test were almost as good as in the cross-validation, obtaining an R p of 0.79, R 2 of 0.64 and an RMSE of 0.97 ( Fig S1, Text S2 ). The accuracy of the predictions encouraged us to train the networks with fewer IC 50 values. Remarkably, the predictive power of the models did not fall appreciably off in quality, even if the amount of training data was reduced to 20 % of the total (Fig 3B) .
Using an analysis of variance (ANOVA) to identify drug-to-oncogene associations, we investigated how well the IC 50 values predicted for the test set using our model recapitulate associations manifested in the experimental data, for instance, whether a given mutation is causing sensitivity or resistance against a drug [3] . Fig S3) .
Discussion
Our results show that by using genomic features from the cell lines and chemical information from drugs, it is possible to build in silico multi-drug models to impute missing IC 50 values with non-parametric machine learning algorithms such as neural networks and random forests. As output for our method, we chose to explore IC50 values as generated by Garnett et al. [3] , which enables us to compare our results to them, however other metrics (such as a capped IC50 or area under the curve), might provide additional insight and potentially lead to more robust models.
The Pearson correlation ( Fig. 2A) and coefficient of determination (Fig. 2B ) of the multi-drug model are significantly better than the single-drug models, while the RMSE error is similar (Fig 2C) . This means that the error (on average) of predicting a given IC50 value is the same in the multi-drug and single-drug models (RMSE) and, since some drugs are active at different concentration ranges, the model is able to cover a much larger dynamic range with a similar precision. The coefficient of determination balances these two terms, and thus a broader range with the same RMSE increases R 2 . Thanks to the use of chemical descriptors, multi-drug models are trained with a volume of data that is two orders of magnitude bigger than the data to train each single-drug model. This larger dataset weights the difficulty in training heterogeneous response values across drugs.
In several instances, the use of multi-drug models permitted the in silico identification of genomic events associated with altered drug sensitivity, which is only possible when genomic properties are considered.
Although our models did not capture all known gene to drug associations, we anticipate that as larger drug sensitivity and genomic datasets become available in coming years the predictive power of these models will increase. We believe that the predictive power of our models is due to the large number of cell lines and broad range of drugs in the GDSC panel that samples intensively the chemical space of common cancer drugs (chemotherapeutic and kinase inhibitors). It remains to be determined how these models will predict completely unknown families of therapeutic agents. . Prior knowledge could also increase the interpretability of the results. Known regulatory relationships between genes and transcriptional data [33] and protein networks [34] can be used to identify deregulated pathways, and be further linked to the genomic alterations that drive them [35] , highlighting subnetworks of importance for drug response.
Incorporation of these additional features will require a scheme to prioritize the input features based on their impact on the final trained model. Associations between features and outcomes could be explicitly unveiled by integrating in our models feature selections criteria and dimensionality reduction techniques.
In terms of predictive models, we have used standard machine learning methods (neural networks and random forests), given their flexibility and robustness as predictive models. A fertile ground for further research is investigating the application of other modeling techniques, including linear regression methods (e.g. LASSO, ElasticNets).
Our results also show that one can estimate the accuracy of prediction for different degrees of sparseness in the data, which may have utility when designing experiments where coverage has to be balanced with accuracy. Furthermore, because models are able to predict IC 50 on cell lines not screened yet, predictions from these models can be used to decide whether it is worthwhile expanding the panel of cell lines, or rather focus on a few selected ones. on clinically approved drugs is expected to reveal candidates for drug repurposing and potentially identify specific disease sub-types that would be most responsive [8] . Although cell lines are not an exact replica of real tumours, comprehensive predictive models such as ours together with expanded genomic and epigenomic datasets may be a good proxy to facilitate the development new therapeutic strategies tailored to individual patients [12] .
Materials and Methods
Training dataset -We used the data from the Genomics of Drug Sensitivity in Cancer project [3] , which contains 639 cancer cell lines, each of them characterised by a set of genomic features (details in the next section). The characterisation is not complete for every cell line, and therefore we filtered out cell lines with more than 15 missing genomic features, which reduced the set of selected cell lines from 639 to 608. The dataset contains 131 drugs. As our method exploits the chemical structure of each drug, this information in simplified molecular-input line entry system (SMILES) format is required. Therefore, we did not consider the 20 drugs for which SMILES were not available, and built our model for the remaining 111 drugs. However, a few mutational features are missing for some cell lines, and we conservatively removed a feature in case it was missing for any cell line. This led to a final set of 138 genomic features characterising each cancer cell line. Taking together the cancer cell line and drug stream, we used 827 features to build our predictive models of the log IC 50 value of a given cell line in the presence of a given drug.
Cross-validation -We used an 8-fold cross-validation for building our models. Therefore, we separated the original dataset into eight equally sized sets of IC 50 values, obtained by randomly distributing all IC 50 s of the matrix into 8 bins. One of them was exclusively used for testing (never involved in any training), other six were destined for training the model and the remaining piece was used for cross-training. Crossvalidation is a process used to avoid under-and overfitting [36] e.g. identifying the optimal number of hidden units and training iterations for a neural network (details in "Machine learning" section). We rotated iteratively the sets so that each data point was used at least once for training, cross-training or testing.
Finally, we obtained 8 models, which were equally predictive.
Furthermore, we used a more stringent version of the above described 8-fold cross-validation. We ensured that test, train and cross-train set are not sharing any cell line, which might occur in the nonstringent version (described above). For instance, assume cell line C1 is treated with the drugs D1, D2 and D3; For the non-stringent cross-validation, the combination C1-D1, C1-D2 and C1-D3 might be distributed over test, train and cross-train set; for the stringent cross-validation, every combination with C1
is exclusively occurring in one of those three sets.
Machine learning -For the neural networks, we used the Java implementation from Encog 3.0.1 (http://www.heatonresearch.com/encog) [37, 38] of a feed-forward multi layer perceptron, where we defined three different layers: input, hidden (or middle) and output layer. Every perceptron of a layer is completely connected to each perceptron of the upper layer. The number of features determined the number of input units, or put it differently, required perceptrons in the first layer. The number of hidden units was explored during the training for determining the correct model complexity, which was between 1 and 30 hidden units. Furthermore, each input and hidden unit had also an bias, which is a permanent activation input for those perceptrons. We used a single output unit for predicting the continuous log(IC 50 ) value.
As perceptron activation function for enabling the network to predict non-linear behaviour, we used the sigmoid function, which returns values in an interval from 0 to 1. Therefore, we had to normalise the IC 50 values (raw IC 50 values, not in log space) also into a range from 0 to 1, which was done with the following logistic-like function:
norm y
where y > 0 y : Observed/expected IC50 value, which has to be a positive number greater than zero.
We trained the network with the resilient error backpropagation implementation from Encog with default parameters [39] . For exploring the final model complexity, which is described by number of hidden units and amount of training iterations, we examined different neural network architectures from 1 up to 30 hidden units and trained them for maximal 400 iterations. We searched the global minimum in that crosstraining landscape (minimizing the root mean square error of cross training set) for avoiding an under-or overfitting (usually, between 21 and 27 hidden units were chosen as best model after approximately 300 iterations).
We also carried out random forest [40] regression models to investigate whether there was any significant performance gain using an alternative non-parametric machine learning methodology (Text S3). A random forest is an ensemble of many different regression trees randomly generated from the same training data (recommended value of n=500 trees was used). 
Size of the test set y  
Size of the test set To further challenge our model and our hypothesis that it is possible to leave out several cell lines, we removed all lung cell lines and used them exclusively for testing. There are 106 out of 608
